

## \*\*\*Pharmacy Notice\*\*\*

## Louisiana Department of Health Bureau of Health Services Financing (Louisiana Medicaid)

## BIN 025986 PCN 1214172240

\*\*\*\*\*Important Notice of Reimbursement\*\*\*\*\*

July 12, 2024

## **Pharmacy Notification**

Hemlibra, Hemgenix, and Roctavian (HEM products) should not have been included in the new clotting factor reimbursement methodology, as these are not factor products. These drugs have now been excluded from the clotting factor reimbursement strategy. Magellan Medicaid Administration (MMA) has identified impacted claims, and are now working to reverse and reprocess.

If you have questions about this notice, call Prime at 888.277.5510, option 1. You can also email your question to <a href="mailto:ProviderRelations@primetherapeutics.com">ProviderRelations@primetherapeutics.com</a> and reference LA MCO Clotting Factor Reimbursement Fee.

Thank you,

Magellan Medicaid Administration